Ingenium Therapeutics
Latest round
- Seed
Last raised
- Dec 2023
Total raised
- $0.9M
Investors
- 2
About Ingenium Therapeutics
, Ltd. is a treatment development company that specializes in the development of anti-cancer cell therapy and related immuno-oncology drugs. The company researches NK cells to develop NK anti-cancer immunotherapy., Ltd., and Maple Investment Partners. The company provides NK cell-based next-generation anti-cancer immune cell therapy for the treatment of patients suffering from refractory acute myeloid leukemia (refractory AML). Ingenium Therapeutics plans to conduct a global clinical trial in 2023.
Who invested in Ingenium Therapeutics
2 investors across 1 round
See all investors in Ingenium Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Dec 12, 2023
Amount
$0.9M
Investors
Questions about Ingenium Therapeutics
Who invested in Ingenium Therapeutics?
Ingenium Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ingenium Therapeutics raised?
Ingenium Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ingenium Therapeutics last raise money?
Ingenium Therapeutics's most recent round on record is a Seed, in Dec 2023.
What does Ingenium Therapeutics do?
Ingenium Therapeutics is a biotechnology company.
Where is Ingenium Therapeutics headquartered?
Ingenium Therapeutics is headquartered in South Korea.
Which VCs invest in companies like Ingenium Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Ingenium Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Ingenium Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.